Skip to main navigation

menu

Aclaris - Corp Menu

About Us »
« Back
Research »
« Back
Partnerships
Products
Careers
Citizenship »
« Back
Insights
Investors »
« Back

Aclaris - Extras Menu

Media resources
Contact us

Aclaris - Corp Menu

About Us »
« Back
Research »
« Back
Partnerships
Products
Careers
Citizenship »
« Back
Insights
Investors »
« Back

Aclaris - Investor Relations

Investor Overview
Stock Information
Press Releases
Events
SEC Filings
Corporate Governance
Investor Presentations
Investor FAQs
Email Alerts

Investor Contact

For investor related questions, please email

investors@aclaristx.com

Investor Overview

Stock quote

VOLUME:

View stock performance »

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Investor Overview

Press Releases

March 15, 2021

Aclaris Therapeutics Completes Enrollment in its Phase 2a Clinical Trial of ATI-1777 for Moderate to Severe Atopic Dermatitis

February 25, 2021

Aclaris Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides a Corporate Update

February 22, 2021

Aclaris Therapeutics to Participate in Upcoming Investor Conferences

Events

Mar 16, 2021
10:00 AM EDT

Aclaris Therapeutics, Inc. at Oppenheimer 31st Annual Healthcare Conference

Mar 9, 2021
7:00 AM EST

Aclaris Therapeutics, Inc. at H.C. Wainwright Global Life Sciences Conference

Feb 25, 2021
8:00 AM EST

Aclaris Therapeutics, Inc. at 10th Annual SVB Leerink Global Healthcare Conference

Feature Presentation

Aclaris Therapeutics Company Overview - March 2021

Aclaris - Footer Menu

Terms of Use
Privacy Policy
Contact Us
Fraudulent Activity Notice

© 2021 Aclaris Therapeutics, Inc. All rights reserved. Unless otherwise noted, all trademarks referenced on this page are owned by Aclaris Therapeutics.